This collaboration underscores Boehringer Ingelheim’s commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada. Based
The post Boehringer Ingelheim, IBM to integrate blockchain technology into clinical trials appeared first on Pharmaceutical Business review.